←
Ro Research Lab41 posts
Ro Research Lab avatar

Ro Research Lab

@RoResearchLab

Exploring the questions shaping health and everyday life through data, research, and insights from the doctors and researchers at Ro.

◷ Joined October 2026▧ 15 Photos and videos
Ro Research Lab avatar
Ro Research Lab@RoResearchLab·Nov 6

The lab coats stay on but the gloves are coming off. Welcome to Ro Research Lab 😈 We’re taking our real-world data about sex, GLP-1s, weight loss, relationships, and more and sharing our insights in real time. Follow along, folks. ro.co/research-lab/

saman rahmanian avatar
⟳ Ro Research Lab retweeted
saman rahmanian@saman·Nov 17

Insurance companies don’t make it easy to know where you stand with your GLP-1 coverage. So we did. Our improved coverage checks and prior authorizations now live in one place on @ro - under your profile. See what's approved, what's in progress and what's next. No phone call required.

0:15
Z Reitano avatar
⟳ Ro Research Lab retweeted
Z Reitano@ZReitano·Nov 16

CVS just put a number on the GLP-1 break-even question. Using Aetna claims, they estimate that at ~$350/month, medical savings roughly offset the drug cost over 3 years. Compared with matched non-users, GLP-1 users had: - 10-12% fewer ER visits in years 1 and 2 - 14% lower odds of a major cardiovascular event - 34-42% fewer hospitalizations among those still on the drug at year 3 At today’s employer prices (~$617-766/mo), plans saved $9,400 per person on medical but spent $13,300 more on Rx. Net: +$3,900. The interesting part: cash prices (~$299-349) and Medicare’s $245 pilot price are already below CVS’s break-even. The barrier isn’t what these drugs can be sold for. It’s what employers are paying. Family coverage now costs $28,303 a year (KFF). That’s why employers are dropping GLP-1s, not because the drugs don’t work. At ~$350/mo, they wouldn’t have to choose. A few call outs: it's a CVS white paper... (insert disclaimers). Observational. Diabetes and obesity pooled. The year-3 group (n≈4,000) is people who stayed on, who may differ from those who stopped. And CVS has a seat at this negotiating table. Affordability drives access.

Ro Research Lab avatar
Ro Research Lab@RoResearchLab·Nov 16

How could they afford to when only 1 in 5 (clinically qualified) people actually can get insurance coverage?

JUST IN: CDC study reveals nearly half of U.S. GLP-1 users don’t take the drugs as prescribed.

Z Reitano avatar
⟳ Ro Research Lab retweeted
Z Reitano@ZReitano·Nov 15

The @RoResearchLab team breaking down just how hard it is to get insurance coverage for GLP1s. We’ve invested a ton of time and energy here to fight for patients at each step but it’s often pushing a boulder up a hill. I’m hopeful as the ROI improves (breadth of label expands, we get more data on benefits of GLP1s and reduction in hc costs are proven out), coverage will increase but I do think it will take a while. Unfortunately, we see large companies like Starbucks and entire states pulling coverage (it’s going in the wrong direction)!

Ro Research Lab @RoResearchLab Nov 15 Article The Denial Industrial Complex: Pulling back the curtain on GLP-1 insurance coverage It's no surprise that insurers have outsized power in who is actually getting access to GLP-1s. But in a new study, we examined coverage outcomes among 225,000 commercially insured patients who were

Ro Research Lab avatar
Ro Research Lab@RoResearchLab·Nov 15

Petrelintide provides two things: ~10% weight loss in 42 weeks, and THE best trial name in the game (ZUPREME!). One thing you won’t get? Nausea and vomiting, which was very similar to placebo... nice #ObesityWeek2026 #OW2026

Post attachment
Ro Research Lab avatar
Ro Research Lab@RoResearchLab·Nov 15

Our abstract on GLP-1 access gaps was covered in the AMJC Journal. Read more about it below 👀 #OW2026 #ObesityWeek

Post attachment

Ro Research Lab @RoResearchLab Nov 15 Article The Denial Industrial Complex: Pulling back the curtain on GLP-1 insurance coverage It's no surprise that insurers have outsized power in who is actually getting access to GLP-1s. But in a new study, we examined coverage outcomes among 225,000 commercially insured patients who were

Ro Research Lab avatar
Ro Research Lab@RoResearchLab·Nov 15

Could GLP-1s play a bigger role in cancer survivorship? We're exploring the possibilities. Weight gain is a common side effect of some cancer treatments, and maintaining a healthy weight is an important part of life after cancer. While GLP-1s may offer a promising option for weight management, more research is needed to understand whether GLP-1 treatment or weight loss could help reduce the risk of cancer recurrence. That's where real-world data can help. We collaborated with @AmericanCancer Society to explore how Ro's data could support future research on GLP-1s among cancer survivors. After further review, we found that cancer survivors make up a meaningful proportion of Ro’s patient population, highlighting an opportunity to help close these research gaps. Research shows that being metabolically healthier is crucial to helping ward off cancer recurrence, and we see an opportunity for Ro Research Lab to help lead the way in answering important questions about GLP-1s, metabolic health, and life after cancer. #OW2026 #obesityweek2026

Post attachment
Neil Floch MD avatar
⟳ Ro Research Lab retweeted
Neil Floch MD@NeilFlochMD·Nov 14

Comparative effectiveness of obesity treatments after initial therapy with semaglutide or tirzepatide: Weight change after taking semaglutide or tirzepatide for 2 years was: −10.9% with continuing the original medication −16.0% with switching between semaglutide and tirzepatide − 8.2% with switching to non- GLP-1 medication −28.2% with undergoing Metabolic Surgery − 4.0% with discontinuation of treatment When GLP-1 fail: MBS is effective @HamletGasoyan @Ali_Aminian_MD #OW2026 thelancet.com/journals/eclin…

Post attachment